Dementia is not a specific disease. It is a descriptive term for a collection of symptoms that can be caused by a number of disorders that affect the brain. People with dementia have significantly impaired intellectual functioning that interferes with normal activities and relationships. They also lose their ability to solve problems and maintain emotional control, and they may experience personality changes and behavioral problems, such as agitation, delusions, and hallucinations.
Last week, the UK Government announced it will be launching the AI Life Sciences Accelerator Mission. Approximately £100 million will be allocated to help drive AI innovation and tackle the UK’s biggest healthcare challenges
Former CEO and Chairman of Google Eric Schmidt, and Ken Griffin, founder and CEO of Citadel and founder of Griffin Catalyst, are today (Monday 30 October) being announced as the first members of a new consortium that will shape the future of the best-in-class UK Biobank.
A new mission announced by the Prime Minister will accelerate the use of AI in life sciences to tackle the biggest health challenges of our generation.
An international team of scientists has identified nearly a dozen genes that contribute to calcium buildup in our coronary arteries that can lead to life-threatening coronary artery disease, a condition responsible for up to one in four deaths in the United States.
The enormous evolutionary success of jellyfish is clear after more than 500 million years on Earth. Nonetheless, they were always seen as primitive creatures with limited learning ability.
In July, the first direct-to-consumer blood test designed to assess a user’s risk for developing Alzheimer’s disease hit the market. The test, which has not undergone Food and Drug Administration (FDA) review, measures the level of a protein called beta amyloid, a key component of plaques that form in the brains of Alzheimer’s disease patients, disrupting brain function.
Viral genetic remnants found naturally in the human genome may influence the development of neurodegenerative diseases.
The Apolipoprotein-ε4 (APOE-ε4) allele has been linked to an increased risk for several types of diseases in aging populations, particularly Alzheimer’s and cardiovascular disease.
Alternative splicing, a clever way a cell generates many different variations of messenger RNAs -; single-stranded RNAs involved in protein synthesis -; and proteins from the same stretch of DNA, plays an important role in molecular biology.
Why do some people develop Alzheimer's disease while others don't? And, even more puzzlingly, why do many individuals whose brains are chock-full of toxic amyloid aggregates-;a telltale sign of Alzheimer's brain pathology-;never go on to develop Alzheimer's-associated dementias?
Neurons in a key area of the brain have different functions based on their exact genetic identity, and understanding this diversity could lead to better understanding of the brain's computational flexibility and memory capacity, potentially informing disease treatment options, Cornell researchers report in a new study.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting tens of millions of people worldwide, and it is the most common cause of dementia.
University of Queensland researchers have used artificial intelligence to build a 3D map of key cell components to better understand dementia and infectious diseases including COVID-19.
New research has discovered that some patients with motor neuron disease (MND) and frontotemporal dementia (FTD) carry the same rare genetic defects that cause other neurodegenerative diseases.
An international research team, comprising scientists from DZNE, University Hospital Bonn, the Netherlands, and the US has been awarded a US$ 1.3 million grant by the "Human Frontier Science Program" to investigate brain immune cells and manipulate them via light irradiation.
Inhibiting a tiny RNA whose levels significantly increase with age, along with problems like weaker bones and sagging muscles, may be a way to keep our bodies more youthful and healthy, scientists say.
Dr Catherine Mummery, a consultant neurologist at UCL Queen Square Institute of Neurology & the National Hospital for Neurology and Neurosurgery, has led a trial. The trial signifies for the first time that a “gene silencing” method has been taken in Alzheimer’s and dementia disease.
In a study published in Nature Communications, a team led by Krembil Brain Institute Senior Scientists, Drs. Lorraine Kalia and Suneil Kalia, and University of Toronto (U of T) Professor, Dr. Philip M. Kim, identified a protein-protein interaction that contributes to Parkinson's disease.
People with dementia have protein build-up in astrocytes that may trigger abnormal antiviral activity and memory loss, according to a preclinical study by a team of Weill Cornell Medicine investigators.
A recent study using mice has revealed a way to turn back the clock after heart attack. The researchers behind the work used RNAs to instruct cells in an injured heart to eliminate scar tissue and recreate cardiac muscle, allowing the heart to function like new again.